Literature DB >> 2127056

Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma.

C W Chen1, H T Huang, J S Bair, C C Lee.   

Abstract

From May 1981 to Feb. 1989 trabeculectomy with per-operative topical application of mitomycin C was performed on eyes with refractory glaucoma. All eyes had undergone prior one, two or more than two antiglaucoma surgeries without success for IOP control. Other risk factors in the present series of eyes included young age, aphakia, rubeosis and glaucoma secondary to trauma or associated with anterior uveitis. 59 eyes underwent trabeculectomy with mitomycin application. 14 eyes were lost. 45 eyes of 42 cases, 33 eyes of 31 males and 12 eyes of 11 females were followed for a period of 1 to 8 years, an average 3.0 +/- 1.9 years. The success for IOP control less than 21 mmHg was 77.8%, 35/45 eyes. The success rates were 92%, 11/12 eyes in females and 73%, 24/33 eyes in males. Complications reported in 5-fluorouracil studies such as corneal epithelial toxicity and delayed healing of conjunctival wound were not encountered. The histo-pathological changes of wound healing after trabeculectomy with topical mitomycin application was discussed. In the healing process success to achieve filtration is more likely by pharmacolocally interferring with earlier steps in the process. We recommend the use of per-operative topical application of mitomycin C during trabeculectomy in eyes with uncontrolled glaucoma and poor prognosis, specifically after previous cataract extraction or unsuccessful antiglaucoma surgery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127056     DOI: 10.1089/jop.1990.6.175

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  81 in total

1.  Biodegradable tube implants in experimental glaucoma surgery in the rabbit.

Authors:  M Kivalo; V Siren; C Raitta; I Immonen
Journal:  J Mater Sci Mater Med       Date:  1999-01       Impact factor: 3.896

Review 2.  Number of people with glaucoma worldwide.

Authors:  H A Quigley
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

3.  Comparison of trabeculectomy and trabeculectomy with amniotic membrane transplantation in the same patient with bilateral glaucoma.

Authors:  Qing-Shan Ji; Bing Qi; Lian Liu; Wei Lao; Zhi-Hao Yang; Gui-Fang Wang; Guo-Cheng Yu; Jing-Xiang Zhong
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

4.  Trypan blue staining of antiproliferative agents for trabeculectomy surgery and bleb needling.

Authors:  W Franks
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  Decorin and suramin inhibit ocular fibroblast collagen production.

Authors:  H Mietz; P Chévez-Barrios; M W Lieberman; M Wendt; R Gross; S F Basinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

6.  Trabeculectomy augmented with mitomycin C application under the scleral flap.

Authors:  S Beatty; T Potamitis; S Kheterpal; E C O'Neill
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

7.  Prevention of hypotony after trabeculectomies with mitomycin.

Authors:  H C Geijssen; E L Greve
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  A randomised, prospective study comparing trabeculectomy with viscocanalostomy with adjunctive antimetabolite usage for the management of open angle glaucoma uncontrolled by medical therapy.

Authors:  D P S O'Brart; M Shiew; B Edmunds
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

9.  Risk factors for flat anterior chamber after glaucoma filtration surgery.

Authors:  Xiang-Ji Li; Richard Filek; Xiang-Ge He; Wei Wang; Hong Liu; Lian He; Yu-Rong Tang; Lin Xie
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

10.  Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery.

Authors:  Qian Han; Yuqi Wang; Xiabin Li; Ribo Peng; Ailing Li; Zhiyong Qian; Ling Yu
Journal:  J Mater Sci Mater Med       Date:  2015-08-19       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.